Patient characteristics
| Subjects, n | 27 |
| Median age, y (range) | |
| Recipient | 52 (19-67) |
| Donor | 39 (24-65) |
| Sex | |
| Male | 11 |
| Female | 16 |
| Race | |
| White | 19 |
| Black | 6 |
| Asian | 2 |
| Disease and disease status at HSCT | |
| AML CR1 with high-risk features* | 5 |
| AML CR2 | 2 |
| AML primary induction failure | 2 |
| AML in resistant relapse | 7 |
| Biphenotypic leukemia with disease at HSCT | 1 |
| ALL CR2 (Ph−) | 3 |
| ALL (Ph+) morphologic remission | 1 |
| MDS | 2 |
| NHL chemotherapy resistant | 3 |
| Aplastic anemia | 1 |
| Previous transplant | 2 |
| Secondary malignancy | 2 |
| Recipient/donor transplantation combinations | |
| Sibling-to-sibling | 7 |
| Parent-to-child | 4 |
| Child-to-parent | 16 |
| CMV serostatus recipient (R) and donor (D) | |
| R+/D+ | 12 |
| R+/D− | 6 |
| R−/D− | 9 |
| HLA antigen mismatches (GVH direction) (A, B, Cw, DRB1), n | |
| 4 | 13 |
| 3 | 11 |
| 2 | 2 |
| 0† | 1 |
| KIR mismatches‡ | |
| HLA-C group 1 | 5 |
| HLA-C group 2 | 4 |
| HLA-Bw4 | 1 |
| HLA-C and HLA-Bw4 | 2 |
| No KIR mismatch | 15 |
| Subjects, n | 27 |
| Median age, y (range) | |
| Recipient | 52 (19-67) |
| Donor | 39 (24-65) |
| Sex | |
| Male | 11 |
| Female | 16 |
| Race | |
| White | 19 |
| Black | 6 |
| Asian | 2 |
| Disease and disease status at HSCT | |
| AML CR1 with high-risk features* | 5 |
| AML CR2 | 2 |
| AML primary induction failure | 2 |
| AML in resistant relapse | 7 |
| Biphenotypic leukemia with disease at HSCT | 1 |
| ALL CR2 (Ph−) | 3 |
| ALL (Ph+) morphologic remission | 1 |
| MDS | 2 |
| NHL chemotherapy resistant | 3 |
| Aplastic anemia | 1 |
| Previous transplant | 2 |
| Secondary malignancy | 2 |
| Recipient/donor transplantation combinations | |
| Sibling-to-sibling | 7 |
| Parent-to-child | 4 |
| Child-to-parent | 16 |
| CMV serostatus recipient (R) and donor (D) | |
| R+/D+ | 12 |
| R+/D− | 6 |
| R−/D− | 9 |
| HLA antigen mismatches (GVH direction) (A, B, Cw, DRB1), n | |
| 4 | 13 |
| 3 | 11 |
| 2 | 2 |
| 0† | 1 |
| KIR mismatches‡ | |
| HLA-C group 1 | 5 |
| HLA-C group 2 | 4 |
| HLA-Bw4 | 1 |
| HLA-C and HLA-Bw4 | 2 |
| No KIR mismatch | 15 |
Based on cytogenetics, secondary disease, CNS/tissue involvement, or arising from MDS.
Patient had 4 mismatches in HVG direction only and was counted for toxicity only
KIR ligand missing in recipient but present in donor. Missing self as defined by Ruggeri et al.18
AML indicates acute myeloid leukemia; CR, complete remission; Ph, Philadelphia chromosome; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; and NHL, nonHodgkin lymphoma.